Liver Cancer Drug Watch
Compounds in Development for Liver Cancer
Updated Feb. 4, 2021
Drug Name |
Mechanism |
Company |
Company Website |
USA Status |
Clinical Trial Website |
|
Nexavar (Sorafenib) |
Raf/Mek/Erk inhibitor |
Bayer |
Approved |
N.A. | |
|
Stivarga (Regorafenib) |
Raf/kit/ret kinase inhibitor |
Bayer |
Approved |
N.A. |
|
|
Opdivo (Nivolumab) |
PD1 inhibitor |
Bristol Myers-Squibb |
Approved |
N.A. | |
|
Lenvima (Lenvatinib) |
VEGFR, PDGFR, FGFR, RET and c-Kit inhibitor |
Eisai |
Approved |
N.A. | |
|
Cabometyx (Cabozantinib) |
VEGFR2, c-MET, RET, KIT, FLT4, AXL inhibitor |
Exelixis |
Approved |
N.A. | |
|
Tecentriq (Atezolizumab) + Avastin (Bevacizumab) |
PD-L1 monoclonal antibody/VEGFA inhibitor |
Genentech |
Approved |
N.A. | |
|
Cyramza (Ramucirumab) |
VEGFR2 inhibitor |
Eli Lilly and Co. |
Approved |
N.A. | |
|
Imfinzi (Durvalumab) + Tremelimumab |
PD-L1/CTLA-4 monoclonal antibody |
AstraZeneca |
Phase II/III (phase II in combination with other drugs or procedures) |
||
|
Cabozantinib + Opdivo (Nivolumab) ± Yervoy (Ipilimumab) |
MET inhibitor, PD1 inhibitor, CTLA-4-blocking antibody |
Exelixis and Bristol-Myers Squibb |
Phase I/II |
||
|
Cabozantinib + Tecentriq (Atezolizumab) vs. Nexavar (Sorafenib) |
MET inhibitor + PD-L1 monoclonal antibody vs. Raf/Mek/Erk inhibitor |
Exelixis |
|||
|
Toripalamib + Lenvatinib |
PD-1/VEGFR2, VEGFR3 antibody |
Shanghai Junshi Bioscience Co. |
Phase III |
||
|
Nexavar (Sorafenib), as adjuvant |
Raf/Mek/Erk inhibitor |
Bayer |
Phase II/III |
||
|
Yiviva (YIV-906) + Sorafenib |
Botanical |
Yiviva Inc. |
Phase IIb |
||
|
Milciclib |
CDK2 Inhibitor |
Tiziana Life Sciences |
Phase II |
||
|
Galunisertib + Sorafenib |
TGF-βR1/VEGFRs, C-KIT, PDGFRB, RAF inhibitor |
Eli Lilly and Co. |
Phase II |
||
|
Tepotinib (MSC2156119J) |
c-MET/HGF inhibitor |
Merck KGaA, Darmstadt, Germany |
Phase 1b/II |
||
|
Galunisertib + Opdivo (Nivolumab) |
TGF-βR1/PD-1 small molecular inhibitor |
Eli Lilly and Co. |
Phase Ib/II |
||
|
Spartalizumab +/- Capmatinib |
PD-1/MET antibody |
Novartis |
Phase Ib/II |
||
|
Pembrolizumab + Nexavar (Sorafenib) |
PD-1/VEGFRs, C-KIT, PDGFRB, RAF inhibitor |
Roswell Park Cancer Institute and Merck Sharpe & Dohme Corp. |
Phase Ib/II |
||
|
Pembrolizumab + Lenvima (Lenvatinib) |
PD-1/VEGFR2, VEGFR3 antibody |
Eisai |
Phase I/III |
||
|
FGF401 +/- Spartalizumab |
FGFR4 inhibitor/PD-1 antibody |
Novartis, through a licensing agreement with EverNov, a subsidiary of Everest Medicines |
Phase I/II complete |
||
|
Mogamulizumab + Opdivo (Nivolumab) |
CCR4/PD-1 antibody |
Kyowa Kirin Pharmaceutical Development, Inc. and Bristol-Myers Squibb |
Phase I/II |
||
|
Pembrolizumab + Keytruda (Epacadostat) |
PD-1/IDO1 antibody |
Incyte Corporation |
Phase I/II |
||
|
Cabozantinib + Opdivo (Nivolumab) |
MET inhibitor, VEGFRs/PD-1 antibody |
Exelixis and Bristol-Myers Squibb |
Phase I/II |
Clinical Trial (after resection) Clinical Trial (with TACE) |
|
|
XL888 + Pembrolizumab |
Hsp90 inhibitor/PD-1 antibody |
Merck Sharpe & Dohme Corp. and Exelixis |
Phase Ib |
||
|
Stivarga (Regorafenib) + Pembrolizumab |
VEGFRs, FGFRs, C-KIT, PDGFRs, RAF/PD-1 antibody |
Bayer and Merck Sharpe & Dohme Corp. |
Phase I |
||
|
Avelumab + Axinitib |
PD-L1/VEGFRs antibody, C-KIT, PDGFRs inhibitor |
Pfizer |
Phase I |
||
|
Cyramza (Ramucirumab) + Imfinzi (Durvalumab) |
VEGFR2/PD-L1 antibody |
Eli Lilly and Co. and AstraZeneca |
Phase I |